Treatment Information

Back

Prostate Cancer treatment details. Chemotherapy.

Memorial Sloan-Kettering Cancer Center, New York, NY, United States.

Survival: monthsCountry:United States
Toxiciy Grade:5City/State/Province:New York, NY
Treatments:ChemotherapyHospital:Memorial Sloan-Kettering Cancer Center
Drugs:Journal:Link
Date:Jun 2011

Description:

Patients:
This phase III study involved men with castration-resistant prostate cancer. Patients were divided into two treatment groups. Group A consisted of 476 patients with a median age of 70.9 years. Group B had 477 patients with a median age of 70.4 years.

Treatment:
Group A was treated with the chemotherapy agent docetaxel and the steroid prednisone. Group B received docetaxel and the chemotherapy agent calcitriol.

Toxicities:
Deaths not due to disease progression were reported for both groups (adverse event grade 5) but specific causes were not given. Grade 3 or higher deep vein thrombosis, anemia, fatigue, and neutropenia were reported.

Results:
The median overall survival was 20.2 months for group A and 17.8 months for group B.

Support:
This study was supported by Novacea, makers of DN-101 (calcitriol).

Correspondence: Dr. Howard I. Scher; email: [email protected]



Back